Publications

Furthering the prostate cancer screening debate (prostate cancer specific mortality and associated risks).

By:
Contributors: Bryan Donnelly, MD, MSc, FRCSC, Dean Ruether, MD FRCSC, Michael Chetner, MD, MSc, FRCSC, FACS, Peter Venner, MD, FRCPC
Can Urol Assoc J. 2011 Dec;5(6):416-21. doi: 10.5489/cuaj.11063.

Abstract

Screening for prostate cancer remains a contentious issue. As with other cancer screening programs, a key feature of the debate is verification of cancerspecific mortality reductions. Unfortunately the present evidence, two systematic reviews and six randomized controlled trials, have reported conflicting results. Furthermore, half of the studies are poor quality and the evidence is clouded by key weaknesses, including poor adherence to screening in the intervention arm or high rates of screening in the control arm. In high quality studies of prostate cancer screening (particularly prostatespecific antigen), in which actual compliance was anticipated in the study design, there is good evidence that prostate cancer mortality is reduced. The numbers needed to screen are at least as good as those of mammography for breast cancer and fecal occult blood testing for colorectal cancer. However, the risks associated with prostate cancer screening are considerable and must be weighed against the advantage of reduced cancerspecific mortality. Adverse events include 70% rate of false positives, important risks associated with prostate biopsy, and the serious consequences of prostate cancer treatment. The best evidence demonstrates prostate cancer screening will reduce prostate cancer mortality. It is time for the debate to move beyond this issue, and begin a well-informed discussion on the remaining complex issues associated with prostate cancer screening and appropriate management.

table

 PubMed

Download PDF

 

Annual Terwillegar Trail Run and Walk Fundraiser

It was a beautiful crisp fall morning for a 10 Km trail run or 7.5 Km walk through the Terwillegar ravine on Saturday, September 29th. The run/walk, hosted by the Terwillegar Trail Run/Walk and the Alberta Cancer Foundation,  is in its 7th year. Its goal is to bring families and friends together to enjoy the outdoors and ultimately raise funds for prostate cancer research.

John Lewis’ research group was out in force; represented by John Lewis, Catalina Vasquez, Arun Raturi, Perrin Beatty and Abbie Coros. Despite the fact that, as one of the run/walk organizers Doug Mitchell pointed out to the participants, John ran in 15-year-old tennis shoes, the Lewis group runners ran well and had a great time!

Funds raised by the Terwillegar Trail Run and Walk go to support cancer research in Alberta. Check out the Alberta Cancer Foundations’ “Dollars at Work” to read about how these funds have been used to support the research from APCaRI members Dr. Frank Wuest and Dr. John Lewis’ labs!

With just over 100 participants this year the 2018 Terwillegar Trail Run/Walk raised over $21 000 for prostate cancer research! You can still donate to this awesome fundraiser, just go to Alberta Cancer Foundation TTRW and click on the Donate Now button!

- Perrin Beatty